Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications...

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Neuroblastoma RAS viral oncogene homolog (RAS) is a key oncogene in melanoma.
• Targeting RAS in melanoma has been challenging due to its complex roles.

Purpose of the Study:

• To investigate the expression and functional roles of five novel RAS splice isoforms in melanoma.
• To determine the potential of these isoforms as biomarkers for therapeutic response and prognosis.

Main Methods:

• Characterization of RAS isoform expression in primary and metastatic melanoma tissues.
• Assessment of phenotypic functions (proliferation, invasion) upon isoform overexpression.
• Analysis of downstream signaling pathways (MAPK, PI3K).
• Evaluation of vemurafenib resistance in cells overexpressing specific RAS isoforms.

Main Results:

• Canonical RAS (isoform-1) expression was highest and increased in metastases.
• Isoform-5 expression in metastases correlated positively with survival and reduced xenograft tumor growth.
• Overexpression of any RAS isoform enhanced proliferation; isoforms 1 and 2 increased invasiveness.
• RAS isoforms differentially activated MAPK and PI3K pathways.
• Isoforms 2 and 5 conferred in vitro resistance to vemurafenib.

Conclusions:

• RAS isoforms exhibit distinct functions in melanoma, influencing proliferation, invasion, and signaling.
• Isoform-5 may serve as a favorable prognostic biomarker.
• RAS isoforms could predict therapeutic response, particularly to BRAF inhibitors like vemurafenib.